---
document_datetime: 2023-09-21 19:45:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lartruvo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: lartruvo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5052628
conversion_datetime: 2025-12-20 16:19:50.565104
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lartruvo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10541 /201704  | Periodic Safety Update EU Single assessment - olaratumab                                                                                                                                                    | 09/11/2017 product                  | 11/01/2018                                     | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10541/201704. |
| II/0006/G            | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or | 12/10/2017                          | n/a                                            |                                  |                                                                                                                                            |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2

A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                         |            | authorised                                           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------|
| R/0004    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                            | 20/07/2017 | 21/09/2017 SmPC and                                  |
| IB/0003/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 07/04/2017 | Annex II 21/09/2017 SmPC, Labelling and PL no longer |
| IB/0001   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS product                                                                                                                                                                                                                                                                           | 10/02/2017 | n/a                                                  |
| IA/0002   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation Medicinal                                                                                                                                                                                                                                                               | 03/02/2017 | n/a                                                  |